vTv Therapeutics Inc (VTVT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $78.99M
Last updated: Nov 17, 2026 at 11:05 AM ET
vTv Therapeutics Inc (VTVT) Stock Forecast
Analysts expect vTv Therapeutics (VTVT) to earn -$2.04 per share in the fiscal year ending Dec 31, 2026, on revenue of $30.73M. Of 7 analysts, 7 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 7 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 7 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 7
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$2.04
- EPS consensus, revenue $30.73M
- Fiscal year ending Dec 31, 2027
- -$3.87
- EPS consensus
- Next report
- Mar 8, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$2.04 | -$4.07 to -$1.09 | 4 | $30.73M | N/A | 6 |
| Dec 31, 2027 | -$3.87 | -$4.81 to -$2.46 | 6 | N/A | N/A | 6 |
Quarterly Estimates
The EPS consensus rises from -$1.29 for the quarter ending Dec 31, 2026 to -$1.08 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$1.29 | -$1.42 to -$1.13 | 9 |
| Mar 31, 2027 | -$1.08 | -$1.21 to -$1.00 | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$2.41.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$2.04 | -$1.71 | -$2.22 | -$2.22 | -$2.41 | N/A |
| Fiscal year ending Dec 31, 2027 | -$3.87 | -$4.38 | -$4.70 | -$4.70 | -$4.21 | N/A |
| Quarter ending Mar 31, 2027 | -$1.08 | -$1.11 | -$1.11 | -$1.11 | -$1.00 | N/A |
Frequently Asked Questions About VTVT
What is the VTVT stock forecast?
Consensus analyst estimates put vTv Therapeutics's EPS at -$2.04 for the fiscal year ending Dec 31, 2026, on revenue of $30.73M. The consensus rating from 7 analysts is Buy.
How do analysts rate VTVT stock?
Of 7 analysts covering vTv Therapeutics, 0 rate it Strong Buy, 7 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from VTVT next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.04, with estimates from -$4.07 to -$1.09 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$3.87, with estimates from -$4.81 to -$2.46 from 6 analysts.
What revenue do analysts expect from vTv Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $30.73M.
How many analysts cover VTVT?
7 analysts rate vTv Therapeutics stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
VTVT pages: Overview, Earnings, Forecast, Financials, Competitors